Literature DB >> 24898652

Cognitive enhancers (Nootropics). Part 1: drugs interacting with receptors. Update 2014.

Wolfgang Froestl1, Andreas Muhs1, Andrea Pfeifer1.   

Abstract

Scientists working in the fields of Alzheimer's disease and, in particular, cognitive enhancers are very productive. The review "Cognitive enhancers (nootropics): drugs interacting with receptors" was accepted for publication in July 2012. Since then, new targets for the potential treatment of Alzheimer's disease were identified. This update describes drugs interacting with 42 receptors versus 32 receptors in the first paper. Some compounds progressed in their development, while many others were discontinued. The present review covers the evolution of research in this field through March 2014.

Entities:  

Keywords:  Alzheimer's disease; cognitive enhancers; memantine; memory; nootropics; receptors

Mesh:

Substances:

Year:  2014        PMID: 24898652     DOI: 10.3233/JAD-140228

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  5 in total

1.  Novel Phospho-Tau Monoclonal Antibody Generated Using a Liposomal Vaccine, with Enhanced Recognition of a Conformational Tauopathy Epitope.

Authors:  Clara Theunis; Oskar Adolfsson; Natalia Crespo-Biel; Kasia Piorkowska; Maria Pihlgren; David T Hickman; Valérie Gafner; Peter Borghgraef; Herman Devijver; Andrea Pfeifer; Fred Van Leuven; Andreas Muhs
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

2.  A new serotonin 5-HT6 receptor antagonist with procognitive activity - Importance of a halogen bond interaction to stabilize the binding.

Authors:  Juan A González-Vera; Rocío A Medina; Mar Martín-Fontecha; Angel Gonzalez; Tania de la Fuente; Henar Vázquez-Villa; Javier García-Cárceles; Joaquín Botta; Peter J McCormick; Bellinda Benhamú; Leonardo Pardo; María L López-Rodríguez
Journal:  Sci Rep       Date:  2017-01-24       Impact factor: 4.379

Review 3.  Serotonin and brain function: a tale of two receptors.

Authors:  R L Carhart-Harris; D J Nutt
Journal:  J Psychopharmacol       Date:  2017-08-31       Impact factor: 4.153

4.  Adenosine A2A Receptor Occupancy by Caffeine After Coffee Intake in Parkinson's Disease.

Authors:  Kenji Ishibashi; Yoshiharu Miura; Kei Wagatsuma; Jun Toyohara; Kiichi Ishiwata; Kenji Ishii
Journal:  Mov Disord       Date:  2022-01-09       Impact factor: 9.698

Review 5.  Addressing the Neuroprotective Actions of Coffee in Parkinson's Disease: An Emerging Nutrigenomic Analysis.

Authors:  Lai Kuan Lee; Nur Anis Raihana Mhd Rodzi
Journal:  Antioxidants (Basel)       Date:  2022-08-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.